EPI

Harris Williams Advises D&H United Fueling Solutions on its Sale to Wind Point Partners

Retrieved on: 
Friday, September 23, 2022

Harris Williams , a global investment bank specializing in M&A advisory services, announces it advised D&H United Fueling Solutions (D&H United), a portfolio company of KLH Capital (KLH), on its sale to Wind Point Partners (Wind Point).

Key Points: 
  • Harris Williams , a global investment bank specializing in M&A advisory services, announces it advised D&H United Fueling Solutions (D&H United), a portfolio company of KLH Capital (KLH), on its sale to Wind Point Partners (Wind Point).
  • We continue to see strong investor appetite for companies like D&H United that provide mission-critical, non-deferrable services in fragmented industries, said Graham Gillam, a director at Harris Williams.
  • Wind Point is currently investing out of Wind Point Partners X, a fund that was initiated in 2022.
  • Harris Williams is a trade name under which Harris Williams LLC, Harris Williams & Co. Ltd and Harris Williams & Co. Corporate Finance Advisors GmbH conduct business.

onsemi Expands its Silicon Carbide Fab in the Czech Republic

Retrieved on: 
Wednesday, September 21, 2022

onsemi (Nasdaq: ON), a leader in intelligent power and sensing technologies, today celebrated the inauguration of its expanded silicon carbide (SiC) fab in Roznov, Czech Republic.

Key Points: 
  • onsemi (Nasdaq: ON), a leader in intelligent power and sensing technologies, today celebrated the inauguration of its expanded silicon carbide (SiC) fab in Roznov, Czech Republic.
  • View the full release here: https://www.businesswire.com/news/home/20220921005803/en/
    onsemi expands Roznov Silicon Carbide Fab (Photo: Business Wire)
    Starting in 2019, onsemi added SiC polished wafer and SiC epitaxy (EPI) wafer production to its existing silicon polished and epitaxy wafer and die manufacturing in Roznov.
  • Having outgrown the original site, reconstruction of a new building began last year to further expand wafer and SiC EPI manufacturing.
  • onsemi and the onsemi logo are trademarks of Semiconductor Components Industries, LLC.

Eco Partnering Innovations, Miller Alliance Group and Ubicquia Announce Strategic Partnership to Help Agencies Better Manage Traffic

Retrieved on: 
Tuesday, September 20, 2022

FORT LAUDERDALE, FL, Sept. 20, 2022 /PRNewswire-PRWeb/ -- Eco Partnering Innovations (EPI) and Miller Alliance Group (MAG), Smart City technology solution providers and experts within ITS, Traffic and Planning and Ubicquia, Inc., a company dedicated to making intelligent infrastructure platforms that are simple to deploy and monitor, announce a strategic partnership. The organizations are collaborating to provide agencies with better insights into traffic safety and the intelligence required to increase traffic efficiency.

Key Points: 
  • The organizations are collaborating to provide agencies with better insights into traffic safety and the intelligence required to increase traffic efficiency.
  • Agencies are looking for flexible systems that can help them understand traffic patterns, improve congestion and reduce air pollution from cars.
  • "Miller Alliance Group, LLC is excited to represent Ubicquia within the Smart City marketplace of the Carolinas," said Lori Miller, Principal-Owner of Miller Alliance Group, LLC.
  • "We are honored to represent Ubicquia in the Florida ITS, Traffic & Planning marketplace," said Stephanie Hoback, Principal/Owner of Eco Partnering Innovations, LLC.

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

Retrieved on: 
Monday, September 19, 2022

BOCA RATON, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Stockholders to provide an update on the Companys clinical programs and recent events.

Key Points: 
  • BOCA RATON, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Stockholders to provide an update on the Companys clinical programs and recent events.
  • We anticipate that this trial will commence prior to year-end 2022, subject to FDAs acceptance of the IND.
  • For those new to First Wave BioPharma, adrulipase is our most clinically advanced asset and we believe it offers the potential to be a best-in-class treatment for EPI associated with CF and CP.
  • As many of our stockholders are painfully aware, the first nine months of 2022 have been a difficult time for biotechnology stocks of all sizes.

First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Fall Webconference

Retrieved on: 
Wednesday, September 14, 2022

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Key Points: 
  • First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP).
  • First Wave BioPharma is headquartered in Boca Raton, Florida.
  • Longwood Healthcare Leaders meetings bring together leading biotech and pharma CEOs, heads of R&D, top academics, and healthcare investors for off-the-record discussions to drive transparency and collaboration in order to accelerate the translation of discoveries into medicines to help patients.

Olympus Announces U.S. Distribution of EndoClot Polysaccharide Hemostatic Spray and EndoClot Submucosal Injection Agent

Retrieved on: 
Monday, September 12, 2022

CENTER VALLEY, Pa., Sept. 12, 2022 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today it will distribute EndoClot® Polysaccharide Hemostatic Spray and EndoClot® Submucosal Injection Solution, two important products developed by EndoClot Plus, Inc. (EPI), which joined with Olympus in a U.S. distribution agreement earlier in the year.

Key Points: 
  • Based on EndoClot AMP Technology, Submucosal Injection Solution (SIS) and Polysaccharide Hemostatic Spray (PHS) Systems Assist with Submucosal Lift and Hemostasis During GI Procedures
    CENTER VALLEY, Pa., Sept. 12, 2022 /PRNewswire/ --Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today it will distribute EndoClot Polysaccharide Hemostatic Spray and EndoClot Submucosal Injection Solution, two important products developed by EndoClot Plus, Inc. (EPI), which joined with Olympus in a U.S. distribution agreement earlier in the year.
  • The starch-derived AMP technology has demonstrated an excellent safety profile.iThe EndoClot AMP particles work by absorbing water from blood.
  • "We see great advantage in being able to identify the bleed and address it at the same time."
  • The EndoClot PHS System enables physicians to apply an advanced powder hemostat during a procedure using controlled, consistent air pressure through a portable air compressor.

First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

Retrieved on: 
Wednesday, September 7, 2022

BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule drug delivery formulation for the ongoing development of its adrulipase clinical program (FW-EPI). First Wave BioPharma now plans to submit an Investigational New Drug (IND) amendment to the U.S. Food & Drug Administration (FDA) for a Phase 2 “proof-of-concept” clinical study investigating the optimized version of adrulipase as a treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). First Wave BioPharma expects to initiate the Phase 2 trial prior to year-end 2022 following acceptance of the IND.

Key Points: 
  • BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule drug delivery formulation for the ongoing development of its adrulipase clinical program (FW-EPI).
  • First Wave BioPharma expects to initiate the Phase 2 trial prior to year-end 2022 following acceptance of the IND.
  • The selection of the enteric microgranule drug delivery technology follows extensive research by First Wave BioPharma and our drug delivery formulation partner, Pace Life Sciences, into the development and manufacturing of the optimized adrulipase formulation, said James Sapirstein, President and CEO of First Wave BioPharma.
  • Additionally, First Wave BioPharma previously published a white paper detailing the development of the microgranule formulation for adrulipase.

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract

Retrieved on: 
Wednesday, August 31, 2022

BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, announced today that an abstract titled, Formulation Development of Enterically Protected Spray Dried Dispersions of Adrulipase, has been accepted at AAPS 2022 PharmSci 360 .

Key Points: 
  • BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, announced today that an abstract titled, Formulation Development of Enterically Protected Spray Dried Dispersions of Adrulipase, has been accepted at AAPS 2022 PharmSci 360 .
  • We are very pleased that First Wave and Paces research into the development of a microgranule delivery formulation for adrulipase was accepted for presentation at the AAPS 2022 PharmSci 360 conference, said James Sapirstein, President and CEO of First Wave BioPharma.
  • We are excited to report that an optimal microgranule formulation has been developed, and we now look forward to initiating a clinical trial utilizing this formulation this year.
  • First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022

Retrieved on: 
Monday, August 29, 2022

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Key Points: 
  • First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP).
  • The company is also advancing multiple programs involving niclosamide, including FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and FW-CD for Crohns disease.
  • First Wave BioPharma is headquartered in Boca Raton, Florida.

Piper-Heidsieck, Charles Heidsieck, and Rare Champagne Achieve B Corp Certification

Retrieved on: 
Monday, August 29, 2022

NAPA, Calif., Aug. 29, 2022 /PRNewswire-PRWeb/ -- Champagnes Piper-Heidsieck, Charles Heidsieck & Rare Champagne, part of the family-owned EPI Group, are delighted to announce that the three producers have achieved B Corp certification status with the score of 91.9 points, verified by B Lab, the non-profit network founded in 2006. Through this certification, these three iconic Houses in Champagne are strengthening their commitments to both social and environmental issues. This represents a crucial step in the reinvention of their practices towards a positive and purpose-driven business model.

Key Points: 
  • Through this certification, these three iconic Houses in Champagne are strengthening their commitments to both social and environmental issues.
  • B Corp Certification involves being accountable to all stakeholders, not just shareholders, and being transparent by allowing information about one's performance to be measured against B Lab standards and publicly available on its B Corp profile on the B Lab website.
  • B Corp certification does not just assess a product or service.
  • "I am particularly proud of the tremendous work accomplished by the teams at Champagnes Piper-Heidsieck, Charles Heidsieck & Rare to achieve the profound transformation required for B Corp certification, and we will only continue to improve moving forward," adds Lafaurie.